Gossamer Bio, Inc. (GOSS) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Gossamer Bio, Inc. (GOSS) Earnings Overview
As of June 13, 2026, Gossamer Bio, Inc. (GOSS) reported trailing twelve-month net income of -$180M, reflecting -200.0% year-over-year growth. The company earned $-0.77 per diluted share over the past four quarters, with a net profit margin of -351.5%.
Looking at the long-term picture, GOSS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$83,000 in fiscal 2016.
Gossamer Bio, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARWR (-$301M net income, -0.2% margin), MNKD (-$24M net income, 1.7% margin), AVXL (-$40M net income), GOSS has room to improve margins relative to the peer group. Compare GOSS vs ARWR →
GOSS Earnings vs Peers
Earnings metrics vs comparable public companies
GOSS Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$170M | -201.4% | -$163M | $-0.75 | -351.5% | -336.8% |
| 2024 | -$57M | +68.6% | -$60M | $-0.25 | -49.3% | -52.2% |
| 2023 | -$180M | +21.6% | -$184M | $-1.18 | - | - |
| 2022 | -$229M | +2.0% | -$219M | $-2.84 | - | - |
| 2021 | -$234M | +3.8% | -$216M | $-3.33 | - | - |
| 2020 | -$243M | -34.6% | -$211M | $-3.67 | - | - |
| 2019 | -$181M | -23.0% | -$186M | $-3.30 | - | - |
| 2018 | -$147M | -2070.6% | -$149M | $-2.43 | - | - |
| 2017 | -$7M | -8057.8% | -$7M | $-0.27 | - | - |
| 2016 | $-83,000 | - | $-83,000 | $-0.01 | - | - |
Download Data
Export GOSS earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in GOSS back in 2016?
Total return with dividends reinvested · 10+ years of data
Calculate ReturnsHow much would $100/month in GOSS be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs GOSS Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationGOSS vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowGOSS — Frequently Asked Questions
Quick answers to the most common questions about buying GOSS stock.
What is GOSS earnings per share (EPS)?
GOSS trailing twelve-month (TTM) diluted EPS is $-0.77, reflecting -200.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Gossamer Bio, Inc.'s net income?
Gossamer Bio, Inc. (GOSS) trailing twelve-month net income is $-180M as of 2025. Earnings declined -200.0% year-over-year.
Is GOSS profitable?
GOSS is not currently profitable on a TTM basis, reporting a net loss of $-180M. Net margin is -351.5%. Investors should monitor for a return to profitability.
What is GOSS's earnings growth rate?
GOSS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are GOSS's profit margins?
Gossamer Bio, Inc. net profit margin is -351.5%, operating margin is -336.8%, and gross margin is +97.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is GOSS growing earnings?
GOSS earnings are declining — EPS fell -200.0% year-over-year. TTM net income dropped to $-180M. This contrasts with the 5-year CAGR of N/A.
What was GOSS's best earnings year?
Gossamer Bio, Inc.'s highest annual net income on record is $-83000.00, achieved in fiscal year 2016. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were GOSS's earnings last quarter?
GOSS's most recent reported quarter was Q1 2026. Net income was $-47M with diluted EPS of $-0.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.